A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1
about
A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1
description
clinical trial
@en
klinisch onderzoek
@nl
name
A Phase 3 Study of a Daclatasv ...... Chronic Hepatitis C Genotype 1
@en
A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination
@nl
type
label
A Phase 3 Study of a Daclatasv ...... Chronic Hepatitis C Genotype 1
@en
A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination
@nl
prefLabel
A Phase 3 Study of a Daclatasv ...... Chronic Hepatitis C Genotype 1
@en
A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination
@nl
P1050
P1476
A Phase 3 Study of a Daclatasv ...... Chronic Hepatitis C Genotype 1
@en
P17
P1813
UNITY 4
@en
P3098
NCT02170727
P4844
P580
2014-06-01T00:00:00Z
P582
2015-06-01T00:00:00Z